Abstract: The present disclosure relates to compositions and methods for the treatment of topical skin conditions. Also provided are topically applied compositions and delivery systems. Also provided are methods of using the compositions and delivery systems in cosmetic, personal care and dermatology applications. Also provided is a sprayable composition that comprises petrolatum.

Abstract: Aspects of the disclosure relate methods and synthetic scaffolds for regenerating hollow tubular organs present in the respiratory system such as bronchus tissue.

Abstract: Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.

Abstract: The invention provides a dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a methane inhibitor to the animal over a period of time. Preferably the methane inhibitor is a haloform. Also provided is the use of the bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Abstract: Compositions and methods for improving gastrointestinal function and reducing the presence of gas bubbles in a gastrointestinal tract. A composition includes an effective amount of ginger root extract for reducing gas bubbles in a gastrointestinal tract and further includes propylene glycol and sodium chloride.

Abstract: The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of transdermal delivery systems, patches, vehicles and devices including an iontophoretic transdermal delivery system, patch, vehicle or device used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: This invention concerns the incorporation of curcumin into the backbone of a hydrolytically degradable crosslinked hydrogel that utilizes poly(beta amino ester) (PBAE) chemistry to provide a tunable protective network with the ability to release at a controlled rate. Upon the introduction of these microparticle systems in to a free radical generating environment, the constituent amount of curcumin present in solution was improved in comparison to a free curcumin state. From these results, a kinetic rate model was developed to estimate oxidative consumption parameters of curcumin and curcumin monoacrylate and quantify theoretical levels of free radicals present depending on the rate of release of curcumin provided. Modeled curcumin conjugated PBAE microparticles improve translation and overall success in delivering a therapeutic agent that matches levels of oxidative stress.

Abstract: A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active pharmaceutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Abstract: The present invention relates to a fluid composition intended for the protection of keratin materials against ultraviolet radiation, characterized in that it comprises at least: (a) a photoprotective system capable of screening out UV radiation, (b) at least one diester of a C2-C8 carboxylic acid and of a C1-C4 alcohol, (c) at least one diester of a C9-C14 carboxylic acid and of a C1-C4 alcohol, (d) at least one (C4-C26) dialkyl ether. The present invention relates more particularly to aqueous vaporizable compositions in particular in spray form and also to the pressurization devices containing them.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: The invention provides a pharmaceutical composition suitable for topical application. The pharmaceutical composition comprises an extract of Plectranthus aliciae and a pharmaceutically acceptable carrier. The invention extends to provide a pharmaceutical composition for the treatment of acne, a pharmaceutical gel composition, a substance or composition comprising an extract of Plectranthus aliciae, a use of a Plectranthus aliciae extract, and various methods of preventing or treating acne.

Abstract: The present subject matter includes novel chemical formulations having antimicrobial, antifungal, antiseptic, and related effect in a wide range of applications for treating or preventing infections as well as treating various surfaces that may become tainted with infectants. In some embodiments, the formulation includes isoamyl hexanoates and at least one of propanoic and/or isobutyric acid.

Abstract: A subcritical liquid extraction process for the production of oleandrin or oleandrin-containing extract is provided. The process provides improvements over other methods of preparing oleandrin-containing extract. The extract, pharmaceutical compositions, dosage forms and nutraceutical compositions comprising oleandrin or said extract are provided. Methods of treating diseases, disorders or conditions that are therapeutically responsive to oleandrin are also provided.

Abstract: A method is described of stabilizing the pH of an aqueous composition including a drug that is prone to oxidation. The method includes adding an additive to prevent oxidation of the drug that is prone to oxidation. Also described, is a method of stabilizing the pH of an aqueous composition including a corticosteroid, the method including adding an additive to prevent oxidation of the corticosteroid. Further, a composition is described that includes a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: A composition for treating night blindness includes Coccinia grandis (L.) stem and goat liver for the treatment of night blindness. The composition is edible and demonstrates remarkable therapeutic results when administered to a patient suffering from night blindness. In an embodiment, the composition can cure night blindness within 3 to 5 days of treatment.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.